TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

Grand News Network | November 8, 2023

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023. This will take place November 10–15 at the San Diego Convention Center in San Diego, California. TLC599 is a proprietary BioSeizer® sustained release injectable in development for the treatment of osteoarthritis pain.

Details of the event and presentation are as follows:  
 
Session: Late-Breaking Abstracts
Time / Date:  8:30am - 8:45am, Wednesday, November 15, 2023
Abstract ID: 1651410
Final Number: L19
 Abstract Title: A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
   

"We are pleased that the ACR has recognized the importance of this Phase 3 data by selecting it for presentation," said Dr. David Hunter, Florance and Cope Chair of Rheumatology at University of Sydney and principal investigator on the Phase 2 and Phase 3 clinical trials for TLC599. "The data from this pivotal Phase 3 trial demonstrates the sustained efficacy and safety of TLC599 out to 52 weeks. We look forward ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner